Table 3. Glycemic Control and Kidney Function Changes Posttreatment in the IPTW of Propensity Score With 5% Cohort Trimming.
| Variable | SGLT2 inhibitors | GLP-1 RAs | ASMDa |
|---|---|---|---|
| Baseline HbA1c, median (IQR), % | 8.6 (7.7-9.7) | 8.9 (8.0-9.8) | 0.05 |
| HbA1c, median (IQR), % | |||
| 1 y | 7.8 (7.1-8.7) | 7.8 (7.0-8.8) | <0.01 |
| 2 y | 7.8 (7.1-8.6) | 7.8 (7.0-8.8) | 0.02 |
| 3 y | 7.7 (7.0-8.5) | 7.7 (6.9-8.7) | 0.02 |
| Baseline eGFR, median (IQR), mL/min/1.73 m2 | 89.1 (71.2-108.8) | 90.9 (68.3-114.4) | 0.02 |
| eGFR, median (IQR), mL/min/1.73 m2 | |||
| 1 y | 87.6 (69.2-107.9) | 88.4 (66.3-113.2) | <0.01 |
| 2 y | 85.7 (67.2-105.1) | 85.1 (63.4-109.6) | <0.01 |
| 3 y | 84.9 (66.6-104.5) | 85.1 (61.8-103.8) | 0.01 |
| Baseline UACR, median (IQR), mg/g | 26.8 (9.9-121.7) | 41.0 (11.8-172.2) | 0.02 |
| UACR, median (IQR), mg/g | |||
| 1 y | 28.4 (10.7-119.0) | 39.3 (11.9-148.0) | 0.03 |
| 2 y | 28.4 (10.9-124.0) | 38.9 (14.1-167.0) | 0.03 |
| 3 y | 30.1 (11.4-129.0) | 39.3 (12.8-168.0) | 0.01 |
Abbreviations: ASMD, absolute standardized mean difference; eGFR, estimated glomerular filtration rate; GLP-1 RAs, glucagonlike peptide-1 receptor agonists; HbA1c, hemoglobin A1c; IPTW, inverse probability of treatment weighting; SGLT2, sodium-glucose cotransporter-2; UACR, urine albumin-creatinine ratio.
SI conversion: To convert HbA1c to proportion of total hemoglobin, multiply by 0.01.
a
Values greater than 0.1 indicate a nonnegligible difference between the 2 treatment groups.